Larry has a deep understanding of what drives government enforcement actions, and how to defend against them, in the health care and life sciences industries. As a trial lawyer and then official in the Civil Fraud Section of the U.S. Department of Justice, he litigated and supervised hundreds of False Claims Act and qui tam cases nationally. In his litigation practice, Larry has successfully represented hospitals and health care systems, laboratories, pharmaceutical and device manufacturers, and health care executives against fraud and abuse allegations and investigations brought by federal and state agencies. He is consistently recognized among the nation’s leading health care defense attorneys.
Larry’s health care and life sciences litigation practice focuses on defending clients against allegations and investigations of fraud and abuse involving governmental programs. He is highly experienced in representing clients against actions brought by federal and state agencies including the US Department of Justice (DOJ), the Department of Health and Human Services Office of the Inspector General (HHS OIG), the United States Attorneys’ Offices, and state OIGs and Medicaid Fraud Control Units (MFCUs).
Larry’s practice is based on his 24-years of experience handling complex civil litigation, often in the context of parallel proceedings, and achieving global resolutions. In addition to enforcement defense, Larry counsels clients through internal investigations, corporate compliance, investor due diligence reviews, and health care bankruptcies involving governmental liabilities. His clients include hospitals and health systems, dialysis providers, clinical laboratories, medical equipment companies, pharmaceutical and device manufacturers, and health care executives.
Prior to private practice, Larry served as an Assistant Director with the Civil Fraud Section of the DOJ and focused solely on the False Claims Act and its qui tam provisions. At DOJ he supervised hundreds of qui tam cases filed in US district courts throughout the country, was part of the leadership team for the pharmaceutical enforcement initiative, and managed high-profile actions often involving multiple US Attorneys’ Offices and federal agencies.
Prior to his position as Assistant Director, Larry served with the Civil Fraud Section as a trial attorney focused on health care fraud and defense procurement. He co-led the notable investigation and prosecution of national independent clinical laboratories known as “Operation LABSCAM.” For his achievements, Larry was highly-recognized by the Attorney General with the Department’s highest and second highest awards, as well as multiple awards from the HHS OIG and the MFCUs.
Following law school, Larry served as a law clerk for the Honorable Richard Cardamone of the U.S. Court of Appeals for the Second Circuit.
Larry has a deep understanding of what drives government enforcement actions, and how to defend against them, in the health care and life sciences industries. As a trial lawyer and then official in the Civil Fraud Section of the U.S. Department of Justice, he litigated and supervised hundreds of False Claims Act and qui tam cases nationally. In his litigation practice, Larry has successfully represented hospitals and health care systems, laboratories, pharmaceutical and device manufacturers, and health care executives against fraud and abuse allegations and investigations brought by federal and state agencies. He is consistently recognized among the nation’s leading health care defense attorneys.
Experience
- Represent a major national “Part D” Plan Sponsor in declined qui tam litigations in the Southern District of New York and the District of Rhode Island regarding alleged industry-wide fraud in “Direct and Indirect Remuneration” reporting to CMS.
- Represent a national testing laboratory in a False Claims Act investigation and qui tam matter regarding relationships with hospital-clients, and part of teams representing numerous genetic testing clinical laboratories in qui tam investigations and settlements.
- Represented a $1B urban health care system in a DOJ criminal and civil investigation involving allegations of violations of the Anti-Kickback Statute and Stark Laws with respect to physician compensation, and successfully reached a comprehensive civil settlement.
- Represented a CEO of major Medicaid managed care company with respect to alleged fraud involving Medicaid “medical loss ratio” reporting.
- Represented leading solar distributed power company in False Claims Act investigation involving alleged fraud in connection with U.S. Treasury “1603” program of grants in lieu of tax credits.
- Represented as settlement counsel Tuomey Hospital in its False Claims Act and Stark Law litigation involving physician compensation, and successfully resolved all allegations against it after two trials and appeals.
- Represented a health care system with respect to its only known administrative proceeding by CMS alleging Stark Law violations, and successfully resolved allegations without any liability.
- Represented national dialysis company with respect to a qui tam matter and high-profile internal investigation and whistleblower matters.
- Represented the United States as a DOJ official with respect to hundreds of qui tam actions nationally alleging fraud by hospitals and health systems, clinical laboratories, post-acute providers, dialysis companies, and others with respect to allegations under the False Claims Act, Anti-Kickback Statute, Stark Law, and related criminal and civil enforcement laws.
viewpoints
Tenth Circuit Rejects Request for Rehearing in Closely Watched FCA Medical Necessity Case
November 13, 2018 | Blog | By Samantha Kingsbury, Laurence Freedman
Fifth Circuit Decision is Rare Victory Permitting District Court to Enjoin Recoupment Before Provider Exhausts Administrative Remedies
April 17, 2018 | Blog | By Samantha Kingsbury, Laurence Freedman
Perspective on DOJ Pivot on FCA Enforcement Policy
January 31, 2018 | Blog | By Laurence Freedman
Health Care Enforcement Year in Review and 2018 Outlook: The False Claims Act’s Materiality Standard as Established by Escobar Continues to Evolve
January 4, 2018 | Blog | By Laurence Freedman
Fifth Circuit Limits FCA Liability Due to Lack of “Materiality” in Highway Guardrails Case
November 30, 2017 | Blog | By Laurence Freedman, Samantha Kingsbury
Fifth Circuit Decision in Highway Guardrails Case Provides Important Guidance on Materiality in False Claims Act Cases
November 28, 2017 | Advisory | By Laurence Freedman, Samantha Kingsbury
Implied False Certification Theory Fails in FCA Case Against Billing Agent
August 23, 2017 | Blog | By Laurence Freedman
Hospital and its Clinic Agree to $34 Million Settlement to False Claims Act Allegation that Compensation to Oncologists Violated the Stark Law
May 24, 2017 | Blog | By Laurence Freedman
News & Press
FCA Settlements Demonstrate Importance of Cybersecurity Controls Imposed by Contract
August 20, 2024
Members Scott Lashway, Laurence Freedman, and Special Counsel Matthew Stein published an article in Bloomberg Law about how recent False Claims Act (FCA) settlements show a focus on cybersecurity enforcement. In the article, they outline how organizations with government contracts can mitigate the risk of cybersecurity-related FCA investigations and litigation.
The Best Lawyers in America 2025 Recognizes 184 Mintz Attorneys across 56 Practice Areas
August 15, 2024
187 Mintz attorneys have been recognized by Best Lawyers® in the 2025 edition of The Best Lawyers in America©. Notably, three Mintz attorneys received 2025 “Lawyer of the Year” awards, and 64 firm attorneys were included in the 2025 edition of Best Lawyers: Ones to Watch.
Mintz announced today that 42 of its practices and 83 of its attorneys earned recognition in the 2024 edition of Chambers USA, a guide to the country’s leading law firms. Of those included in the guide, 18 attorneys and seven practice areas were awarded Chambers’ highest ranking, Band 1. The firm obtained new listings in three practice areas and 10 of its lawyers were recognized for the first time.
Mintz is pleased to announce that 120 firm attorneys have been recognized as leaders by Best Lawyers® in the 2024 edition of The Best Lawyers in America©.
BOSTON –Mintz announced today that 39 of its practices and 81 of its attorneys earned recognition in the 2023 edition of Chambers USA, a guide to the country’s leading law firms.
50 Years In, Industry Has Knives Out For Potent Kickback Law
March 18, 2023
Member Laurence J. Freedman spoke to Law360 about the growing challenges with the Anti-Kickback Statute.
HHS Pans Pfizer's 'Far-Fetched' Kickback Views At High Court
December 14, 2022
Mintz Member Laurence J. Freedman spoke to Law360 about the awaited brief from the U.S. Department of Health and Human Services on whether Anti-Kickback Statute cases should show whether health care "remuneration" intentionally impacted medical decision making.
A Circuit-By-Circuit Guide To FCA Suits After High Court Snub
November 1, 2022
Mintz Member Laurence Freedman was quoted in a Law360 article exploring the U.S. Supreme Court's refusal to resolve one of the False Claims Act's most consequential controversies and how this is causing a divide in circuit courts.
Best Lawyers® recognized 108 firm attorneys in the 2023 edition of The Best Lawyers in America©. Notably, two Mintz attorneys – Poonam Patidar and Scott M. Stanton – received 2023 “Lawyer of the Year” awards, and 28 firm attorneys were included in the inaugural edition of Best Lawyers: Ones to Watch.
Healthcare Enforcement & Litigation 2022
August 27, 2021
FCA's Epic Run In 2010s Will Be Hard To Match In 2020s
January 29, 2020
2019 Trends In DOJ Civil Health Care Fraud Cases
January 15, 2020
Mintz Recognized by Chambers USA 2019
April 26, 2019
Supreme Court Eyes Hospital Giant's FCA Case
February 25, 2019
Justices Search for Limits of False Claims Act Liability
April 27, 2018
DOJ Says Guidance Documents Can’t Drive Enforcement Actions
January 26, 2018
Attys React To DOJ's New Memo On FCA Dismissals
January 25, 2018
2017 Health Care Enforcement Review: Materiality Under FCA
January 18, 2018
One Year Later, Escobar Is Roiling FCA Landscape
June 16, 2017
Health Care Enforcement Review And 2017 Outlook: Part 3
January 18, 2017
Health Care Enforcement Review And 2017 Outlook: Part 2
January 17, 2017
Does Regulatory Compliance Matter in False Claims Act Cases?
December 29, 2016
Top Gov't Contracts Cases Of 2016
December 12, 2016
Justices Could Tip Power Balance In FCA Seal Dispute
October 31, 2016
U.S. Attorney Changes Mean Opportunities for Fraud Defendants
September 7, 2016
Supreme Court term mixed bag for healthcare industry
July 3, 2016
Senate Finance Mulls Overhaul of Fraud Law
June 30, 2016
SCOTUS Goes Down Middle in False Claims Case
June 17, 2016
Health Fraud Defense Attys Riding High As Wins Pile Up
April 11, 2016
DOJ Aims Torpedo At FCA Sampling Suit In 4th Circ.
March 28, 2016
The Medicare Overpayment Rule: Implications for Compliance and Health Care Enforcement
February 26, 2016
Lookback Period Cut to Six Years in Final Overpayments Rule
February 11, 2016
Health Care Enforcement Reflections and Forecasts: Part 3
January 26, 2016
Health Care Enforcement Reflections and Forecasts: Part 2
January 25, 2016
Health Care Enforcement Reflections and Forecasts: Part 1
January 22, 2016
Health Care Cases to Watch in 2017
January 2, 2016
Events & Speaking
Handling Whistleblower Claims 2022 - Rights of Private Sector Employees
DC Bar Continuing Legal Education
D.C. Bar, Washington, DC
Enforcement Liability & Bankruptcy/Insolvency
ABA 32nd Annual National Institute on Health Care Fraud
Caesars Palace
Handling Whistleblower Claims Series 2021 - Rights of Private Sector Employees
The District of Columbia Bar
Online Event
4th Annual Mintz /ML Strategies Pharmacy & Pharmaceutical Industry Summit
Mintz and ML Strategies
Boston, MA
Handling Whistleblower Claims 2018, Part 2: Rights of Private Sector Employees
DC Bar
Washington, DC
12th Annual ABA Civil False Claims Act and Qui Tam Enforcement National Institute
American Bar Association
Washington, DC
3rd Annual Mintz /ML Strategies Pharmacy & Pharmaceutical Industry Summit
Mintz and ML Strategies
Boston, MA
Compliance Programs and Internal Investigations in Health Care Organizations
Practicing Law Institute
New York, NY
Advanced Compliance Education Webinar Series, Part IV: Compliance for Clinical Laboratories
American Health Lawyers Association
Webinar
ACI's 15th Advanced Forum on Fraud & Abuse in the Sales and Marketing of Drugs
American Conference Institute
Omni Parker House, Boston, MA
Larry has a deep understanding of what drives government enforcement actions, and how to defend against them, in the health care and life sciences industries. As a trial lawyer and then official in the Civil Fraud Section of the U.S. Department of Justice, he litigated and supervised hundreds of False Claims Act and qui tam cases nationally. In his litigation practice, Larry has successfully represented hospitals and health care systems, laboratories, pharmaceutical and device manufacturers, and health care executives against fraud and abuse allegations and investigations brought by federal and state agencies. He is consistently recognized among the nation’s leading health care defense attorneys.
Recognition & Awards
Best Lawyers in America: Health Care Law (2017-2025)
Included on the Washington DC Super Lawyers: Health Care list (2014-202, 2024)
Recognized by the The Legal 500 United States for Healthcare: Service Providers (2015)
US Attorney General’s Award for Exceptional Service (2000)
US Attorney General’s Award for Distinguished Service (1997)
DOJ Special Commendation for Outstanding Service (2003)
DOJ Special Achievement Awards (1997, 2000)
DOJ Meritorious Award (1996)
HHS Inspector General’s Exceptional Achievement Award (1997)
HHS Inspector General’s Integrity Award (1995)
National Association of Medicaid Fraud Control Units Award (1997, 2003)
Phi Beta Kappa
Chambers USA: District of Columbia – Healthcare (2019-2024)
Larry has a deep understanding of what drives government enforcement actions, and how to defend against them, in the health care and life sciences industries. As a trial lawyer and then official in the Civil Fraud Section of the U.S. Department of Justice, he litigated and supervised hundreds of False Claims Act and qui tam cases nationally. In his litigation practice, Larry has successfully represented hospitals and health care systems, laboratories, pharmaceutical and device manufacturers, and health care executives against fraud and abuse allegations and investigations brought by federal and state agencies. He is consistently recognized among the nation’s leading health care defense attorneys.
Involvement
- Member, American Bar Association
- Member, American Health Lawyers Association
- BNA Health Care Fraud Report, Editorial Board Member
- Rx Compliance Report, Advisory Board Member
- Member, Board of Trustees, Temple Sinai (DC) 2018 - 2021
- Sinai Assisted Housing Foundation, Board Member
- Member, Program Committee, AdvaMed 2013